The new availability of AR inhibitors such as bicalutamide, enzalutamide, and apalutamide approved for prostate cancer, suggests the possibility of their use also in AR-positive BC patients, even if AR seems to have different functions depending on BC subtypes (e.g., luminal or TN). This evidence concerns the gene AR and prostate cancer.